AstraZeneca

AstraZeneca restructuring to drive productivity

Friday, February 3, 2012 01:22 PM

In conjunction with the publication of its full year 2011 financial results, AstraZeneca is enacting new restructuring initiatives that will affect approximately 7,300 positions.

More... »

International collaboration to combat 10 neglected tropical diseases by 2020

Monday, January 30, 2012 03:49 PM

Thirteen pharmaceutical companies, the U.S., U.K. and U.A.E governments, the Bill & Melinda Gates Foundation, the World Bank and other global health organizations will join forces to eliminate or control 10 neglected tropical diseases (NTDs) by the end of the decade.

More... »

AstraZeneca, IMS Health team up to use real-world evidence

Wednesday, January 11, 2012 03:40 PM

AstraZeneca has entered into a three-year collaboration agreement with IMS Health, a leading provider of healthcare information, services and technology, to further the use of real-world evidence based on observational and retrospective studies.

More... »

AstraZeneca, Chi-Med collaborate to develop novel cancer therapy

Friday, December 23, 2011 11:47 AM

AstraZeneca and Hutchison MediPharma, an R&D company majority owned by Chi-Med, have entered into a global licensing, co-development, and commercialization agreement for Volitinib (HMPL-504), a novel targeted therapy and a highly selective inhibitor of the c-Met receptor tyrosine kinase for the treatment of cancer. Volitinib, which will imminently enter phase I testing, has been discovered and developed in China by HMP.

More... »

AstraZenca to cut 1,150 US sales positions

Wednesday, December 7, 2011 01:56 PM

AstraZeneca will reduce its U.S. sales force by approximately 1,150 leadership positions and sales representatives as part of the company’s ongoing strategy to operate its business more efficiently to best serve patients in the United States.

More... »

AstraZeneca, MRC ink collaboration giving UK academia access to 22 compounds

Monday, December 5, 2011 02:14 PM

A wide range of compounds will be made available free of charge to UK medical researchers next year, following an agreement between the Medical Research Council (MRC) and AstraZeneca. Academia will be granted access to 22 compounds, developed by AstraZeneca. Through MRC funding, UK academia will conduct studies to better understand what drives a range of diseases with a view to exploring new treatment opportunities.

More... »

AstraZeneca, Cognizant sign multi-year agreement

Wednesday, November 30, 2011 11:10 AM

More... »

AstraZeneca commits additional $100m to MedImmune

Tuesday, November 29, 2011 02:22 PM

AstraZeneca has committed an additional $100 million to its venture capital arm, MedImmune Ventures, increasing the total capital under management to $400 million. MedImmune Ventures is an evergreen venture capital fund that focuses on equity investments in private companies in the areas of biopharmaceuticals, medical and healthcare technology.

More... »

U-M Medical School, MedImmune ink 3 year research agreement

Wednesday, November 23, 2011 09:42 AM

Leaders from the University of Michigan Medical School and MedImmune, the global biologics arm of AstraZeneca, have signed a new agreement to work together on a broad range of projects. The three-year strategic collaboration will bring scientists from one of the nation’s top medical research institutions together with scientists from one of the world’s leading developers of biologic therapies. UMMS and MedImmune scientists will cooperate on studies that aim to translate scientific discoveries from the laboratory into new candidates for treating cancer, heart disease, digestive disease, lung disease and diseases caused by inflammation.

More... »

AgonOx, MedImmune partner to develop cancer therapies

Monday, October 31, 2011 11:57 AM

AgonOx has entered into an exclusive global partnership with MedImmune, the global biologics arm of AstraZeneca, to develop agonists using its OX40 platform. MedImmune will lead further preclinical and clinical studies of this tumor-specific T-cell immunity stimulator for the potential treatment of cancer.

More... »